386 related articles for article (PubMed ID: 34464977)
21. Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma.
Tang S; Ma D; Cheng B; Fang Q; Kuang X; Yu K; Wang W; Hu B; Wang J
Exp Cell Res; 2018 Feb; 363(2):196-207. PubMed ID: 29317217
[TBL] [Abstract][Full Text] [Related]
22. Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
Yu C; Friday BB; Yang L; Atadja P; Wigle D; Sarkaria J; Adjei AA
Neuro Oncol; 2008 Jun; 10(3):309-19. PubMed ID: 18445700
[TBL] [Abstract][Full Text] [Related]
23. The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin.
Lemaire M; Fristedt C; Agarwal P; Menu E; Van Valckenborgh E; De Bruyne E; Österborg A; Atadja P; Larsson O; Axelson M; Van Camp B; Jernberg-Wiklund H; Vanderkerken K
Clin Cancer Res; 2012 Apr; 18(8):2230-9. PubMed ID: 22392915
[TBL] [Abstract][Full Text] [Related]
24. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589.
Kauh J; Fan S; Xia M; Yue P; Yang L; Khuri FR; Sun SY
PLoS One; 2010 Apr; 5(4):e10376. PubMed ID: 20442774
[TBL] [Abstract][Full Text] [Related]
25. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
Sanchez E; Shen J; Steinberg J; Li M; Wang C; Bonavida B; Chen H; Li ZW; Berenson JR
Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
[TBL] [Abstract][Full Text] [Related]
26. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.
Ellis L; Bots M; Lindemann RK; Bolden JE; Newbold A; Cluse LA; Scott CL; Strasser A; Atadja P; Lowe SW; Johnstone RW
Blood; 2009 Jul; 114(2):380-93. PubMed ID: 19383971
[TBL] [Abstract][Full Text] [Related]
27. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.
Chen S; Zhang Y; Zhou L; Leng Y; Lin H; Kmieciak M; Pei XY; Jones R; Orlowski RZ; Dai Y; Grant S
Blood; 2014 Oct; 124(17):2687-97. PubMed ID: 25208888
[TBL] [Abstract][Full Text] [Related]
28. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
Zang H; Qian G; Zong D; Fan S; Owonikoko TK; Ramalingam SS; Sun SY
Cancer; 2020 Jan; 126(9):2024-2033. PubMed ID: 31999837
[TBL] [Abstract][Full Text] [Related]
29. The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma.
Jeon YJ; Ko SM; Cho JH; Chae JI; Shim JH
Int J Mol Med; 2013 Oct; 32(4):860-6. PubMed ID: 23877235
[TBL] [Abstract][Full Text] [Related]
30. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
Woods DM; Woan K; Cheng F; Wang H; Perez-Villarroel P; Lee C; Lienlaf M; Atadja P; Seto E; Weber J; Sotomayor EM; Villagra A
Melanoma Res; 2013 Oct; 23(5):341-8. PubMed ID: 23963286
[TBL] [Abstract][Full Text] [Related]
31. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
32. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.
Fiskus W; Pranpat M; Bali P; Balasis M; Kumaraswamy S; Boyapalle S; Rocha K; Wu J; Giles F; Manley PW; Atadja P; Bhalla K
Blood; 2006 Jul; 108(2):645-52. PubMed ID: 16537804
[TBL] [Abstract][Full Text] [Related]
33. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.
Mehrpouri M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M; Bashash D
Eur J Pharmacol; 2020 May; 875():173050. PubMed ID: 32142770
[TBL] [Abstract][Full Text] [Related]
34. Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma.
Ramakrishnan V; Gomez M; Prasad V; Kimlinger T; Painuly U; Mukhopadhyay B; Haug J; Bi L; Rajkumar SV; Kumar S
Oncotarget; 2016 Aug; 7(35):56253-56265. PubMed ID: 27494845
[TBL] [Abstract][Full Text] [Related]
35. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Yang C; Wang H; Zhang B; Chen Y; Zhang Y; Sun X; Xiao G; Nan K; Ren H; Qin S
J Exp Clin Cancer Res; 2016 Sep; 35(1):158. PubMed ID: 27737687
[TBL] [Abstract][Full Text] [Related]
36. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
[TBL] [Abstract][Full Text] [Related]
37. The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells.
Dai Y; Guzman ML; Chen S; Wang L; Yeung SK; Pei XY; Dent P; Jordan CT; Grant S
Br J Haematol; 2010 Oct; 151(1):70-83. PubMed ID: 20701602
[TBL] [Abstract][Full Text] [Related]
38. IAP antagonists induce anti-tumor immunity in multiple myeloma.
Chesi M; Mirza NN; Garbitt VM; Sharik ME; Dueck AC; Asmann YW; Akhmetzyanova I; Kosiorek HE; Calcinotto A; Riggs DL; Keane N; Ahmann GJ; Morrison KM; Fonseca R; Lacy MQ; Dingli D; Kumar SK; Ailawadhi S; Dispenzieri A; Buadi F; Gertz MA; Reeder CB; Lin Y; Chanan-Khan AA; Stewart AK; Fooksman D; Bergsagel PL
Nat Med; 2016 Dec; 22(12):1411-1420. PubMed ID: 27841872
[TBL] [Abstract][Full Text] [Related]
39. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
[TBL] [Abstract][Full Text] [Related]
40. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
